Savara Inc. (Savara, Inc.) aksje
SVRA
Sanntid$5.39+0.14 (+2.76%)
Laster graf...
Savara, Inc.
Market Cap
$1,105,582,336
Åpning5.30
Høy5.43
Lav5.27
Volum263.19k
P/EN/A
Markedsverdi1.11B
52-ukers høy7.01
52-ukers lav1.98
Gj.sn. volum1.53M
UtbytteN/A
Beta0.28
EPS-0.56
Om Savara Inc. (Savara, Inc.) aksje
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Selskapsinformasjon
Børs: NasdaqGS (NMS)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
1717 Langhorne Newtown Road
19047 Langhorne, United States
19047 Langhorne, United States
Telefon: + 512 614 1848
Nettside: https://www.savarapharma.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Anbefaling:1.25 - Stærk køb
Laveste kursmål
9.00
↑ 66.8%
Gjennomsnittlig kursmål
10.81
↑ 100.4%
Median kursmål
10.25
↑ 90.0%
Høyeste kursmål
16.00
↑ 196.6%